Originally published by our sister publication Pharmacy Practice News
Amelia Bond, PhD
Are hospitals participating in the federal 340B Drug Pricing Program less motivated to prescribe biosimilars over their higher priced originator products? That’s the conclusion of a recent study published in Health Affairs (2023;42[5]:632-641) that suggests reforms to the drug discount program are needed to nudge hospitals and providers toward using biosimilars.
The research, from a trio of